Keywords : therapeutics, therapeutic classe
This report provides data on the current developmental pipeline, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews the key players and their products under development for Bacterial Pneumoniae Infections. “Bacterial Pneumoniae Infections-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Industry s Direct’s proprietary databases, primary and second...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
This report provides data on the current developmental pipeline, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews the key players and their products under development for Bacterial Pneumoniae Infections. “Bacterial Pneumoniae Infections-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Industry s Direct’s proprietary databases, primary and secondary research using Firms /University’s website, SEC filings, investor presentations and featured press releases, both from firm /university sites and market -specific third party sources, put together with in-house assessment, by Global Industry s Direct’s team of market experts.
Scope of the Research
- A snapshot of the global therapeutic scenario for Bacterial Pneumoniae Infections.
- Review of the Bacterial Pneumoniae Infections new product development under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Includes new product development based on various stages of development ranging from discovery till registration stages.
- Includes pipeline projects on the basis of monotherapy and combined therapeutics.
- Study of the Bacterial Pneumoniae Infections pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand various therapeutics under development for Bacterial Pneumoniae Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Get an insight into important and diverse types of therapeutics in pipeline for Bacterial Pneumoniae Infections and understand the trends and players likely to impact the global Bacterial Pneumoniae Infections industry in future.
- Devise corrective measures for pipeline projects by understanding Bacterial Pneumoniae Infections pipeline depth and focus and the future of Bacterial Pneumoniae Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and Scope of the Research .
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
- Avoid Intellectual Property Rights related issues.
- Do deals with an understanding of the mergers and partnerships that have shaped the segment .
Global Therapy Industry
1 Table of Contents
I. 1 List of Data tables
I. 2 List of Charts
II Introduction
II. 1 World March kets Direct Report Coverage
III Introduction
III. 1 About Bacterial Pneumoniae Infections
III. 2 An Overview of Bacterial Pneumoniae Infections Therapeutics
IV Bacterial Pneumoniae Infections Therapeutics Development
IV. 1 An Overview of Pipeline Products for Bacterial Pneumoniae Infections
IV. 2 Bacterial Pneumoniae Infections Therapeutics under Development by Firms
IV. 3 Bacterial Pneumoniae Infections Therapeutics under Investigation by Universities/Institutes
IV. 4 Late Clinical Stage Products
IV. 4.1 Comparative Analysis
IV. 4.2 Late Clinical Stage Products - Firms
IV. 4.3 Late Clinical Stage Products - Universities/Institutes
IV. 5 Mid Clinical Stage Products
IV. 5.1 Comparative Analysis
IV. 5.2 Mid Clinical Stage Products - Firms
IV. 5.3 Mid Clinical Stage Products - Universities/Institutes
IV. 6 Early Clinical Stage Products
IV. 6.1 Comparative Analysis
IV. 6.2 Early Clinical Stage Products - Firms
IV. 6.3 Early Clinical Stage Products - Universities/Institutes
IV. 7 Pre-clinical and Discovery Stage Products
IV. 7.1 Comparative Analysis
IV. 7.2 Pre-clinical and Discovery Stage Products - Firms
V Companies Involved in Bacterial Pneumoniae Infections Therapeutics Development
VI Universities/Institutes Involved in Bacterial Pneumoniae Infections Therapeutics Development
VII Bacterial Pneumoniae Infections Therapeutics Assessment
VII. 1 Assessment by Monotherapy Products
VII. 2 Assessment by Combined Therapeutics
VII. 3 Assessment by Therapeutic Class
VII. 4 Assessment by Route of Administration
VII. 5 Assessment by Molecule Type
VII. 5.1 Assessment by Biologics/Non-Biologics under Development
VIII Late Stage Drug Profiles – Firms
VIII. 1 Drug 1 Profile
VIII. 1.1 Product Description
VIII. 1.2 Mechanism of Action
VIII. 1.3 Research and Development Progress
IX Late Stage Drug Profiles – Universities/Institutes
IX. 1 Drug 1 Profile
IX. 1.1 Product Description
IX. 1.2 Mechanism of Action
IX. 1.3 Research and Development Progress
X Bacterial Pneumoniae Infections Therapeutics - Discontinued Firms Products
XI Bacterial Pneumoniae Infections Therapeutics – Featured News
XII Appendix
XII. 1 Research Methodology
XII. 2 Secondary Research
XII. 3 World March kets Direct Consulting
XII. 4 Contact Us
XII. 5 Disclaimer
1.1 List of Data tables
Data table 1: Number of Products under Development, 2010
Data table 2: Bacterial Pneumoniae Infections Products under Development – Comparative Analysis, 2010
Data table 3: Number of Products under Development by Firms , 2010
Data table 4: Number of Products under Investigation by Universities/Institutes, 2010
Data table 5: Comparative Analysis by Late Clinical Stage Development, 2010
Data table 6: Late Clinical Stage Products – Firms , 2010
Data table 7: Late Clinical Stage Products - Universities/Institutes, 2010
Data table 8: Comparative Analysis by Mid Clinical Stage Development, 2010
Data table 9: Mid Clinical Stage Products - Firms , 2010
Data table 10: Mid Clinical Stage Products - Universities/Institutes, 2010
Data table 11: Comparative Analysis by Early Clinical Stage Development, 2010
Data table 12: Early Clinical Stage Products - Firms , 2010
Data table 13: Early Clinical Stage Products - Universities/Institutes, 2010
Data table 14: Comparative Analysis by Pre-clinical and Discovery Stage Development, 2010
Data table 15: Pre-clinical and Discovery Stage Products - Firms , 2010
Data table 16: Firms Involved in Bacterial Pneumoniae Infections Therapeutics Development - Firms 1
Data table 17: Products under Investigation by Universities/Institutes, 2010
Data table 19: Assessment by Monotherapy Products, 2010
Data table 20: Assessment by Combined Therapeutics, 2010
Data table 21: Assessment by Therapeutic Class, 2010
Data table 22: Assessment by Route of Administration, 2010
Data table 23: Assessment by Molecule Type, 2010
Data table 24: Assessment by Biologics/Non-Biologics, 2010
Data table 25: Discontinued Firms Products
1.2 List of Charts
Chart 1: Number of Products under Development, 2010
Chart 2: Bacterial Pneumoniae Infections Products under Development – Comparative Analysis, 2010
Chart 3: Products under Development by Firms , 2010
Chart 4: Products under Investigation by Universities/Institutes, 2010
Chart 5: Late Clinical Stage Products, 2010
Chart 6: Mid Clinical Stage Products, 2010
Chart 7: Early Clinical Stage Products, 2010
Chart 8: Pre-clinical and Discovery Stage Products, 2010
Chart 9: Assessment by Monotherapy Products, 2010
Chart 10: Assessment by Combined Therapeutics, 2010
Chart 11: Comparative Analysis - Monotherapy and Combined Therapeutics, 2010
Chart 12: Assessment by Therapeutic Class, 2010
Chart 13: Assessment by Stage and Therapeutic Class, 2010
Chart 14: Assessment by Route of Administration, 2010
Chart 15: Assessment by Stage and Route of Administration, 2010
Chart 16: Assessment by Molecule Type, 2010
Chart 17: Assessment by Stage and Molecule Type, 2010
Chart 18: Assessment by Biologics/Non-Biologics, 2010
Companies mentioned
